Inmune Bio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $50,000 | $14,000 | $155,000 | $374,000 | $181,000 |
| Research and development | $20.7M | $33.2M | $20.3M | $17.1M | $20.5M |
| Operating expenses | $47.4M | $42.6M | $29.9M | $26.3M | $29.3M |
| Operating income | -$47.4M | -$42.6M | -$29.7M | -$26.0M | -$29.2M |
| Interest expense | — | $789,000 | $2.3M | $2.0M | — |
| Pretax income | $45.9M | $42.1M | $30.0M | — | — |
| Net income | -$45.9M | -$42.1M | -$30.0M | -$27.3M | -$30.3M |
| Balance Sheet | |||||
| Cash and equivalents | $24.8M | $20.9M | $35.8M | $52.2M | $74.8M |
| Current assets | $29.9M | $22.7M | $39.9M | $64.7M | $82.6M |
| Total assets | $32.4M | $39.6M | $57.0M | $81.8M | $99.9M |
| Current liabilities | $8.4M | $7.2M | $18.5M | $10.9M | $4.4M |
| Total liabilities | $8.8M | $7.5M | $18.9M | $21.7M | $19.7M |
| Total debt | — | — | $10.0M | — | — |
| Stockholders' equity | $23.5M | $32.1M | $37.3M | $60.1M | $80.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$22.6M | -$33.4M | -$12.0M | -$22.7M | -$28.5M |
| Depreciation and amortization | $84,000 | — | — | — | — |
| Stock-based compensation | $9.9M | $7.6M | $7.4M | $7.1M | $4.8M |
| Capital expenditure | $1.0M | — | — | — | — |
| Free cash flow | -$23.6M | — | — | — | — |
Shares outstanding 26.6M · Free float 65.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.